Patent

US Patent for Invention No.:US 9,676,834 B2, Date of Patent: Jun. 13, 2017
Title: Fibulin Protein Variants and Corresponding Nucleic Acid Sequences.
Inventor/Applicant: Yi-Hong Zhou

Japan Patent for Invention No. 6163565. Date of Patent: July 12, 2017
Title: Fibulin Protein Variants and Corresponding Nucleic Acid Sequences.
Inventor/Applicant: Yi-Hong Zhou

Chinese Patent for Invention No. ZL201480010754.3. Date of Patent: May 4, 2018
Title: Fibulin Protein Variants and Corresponding Nucleic Acid Sequences.
Inventor/Applicant: Yi-Hong Zhou

European Patent for Invention No. 2981335, Date of Patent: November 14, 2018. National phase in DE, FR, GB
Title: Fibulin Protein Variants and Corresponding Nucleic Acid Sequences.
Inventor/Applicant: Yi-Hong Zhou

US Patent for Invention No. 10,870,690 B2 (Filed: May 31, 2017), Date of Patent: December 22, 2020
Title: “Protein Therapeutant And Method For Treating Cancer”
Inventor/Applicant: Yi-Hong Zhou

Product (for research only)

ZR30, in vitro synthesized protein (SEQ ID NO 14, US 10,870,690 B2) based on sequence of human fibulin-3 variant excluding region encoding signal peptide (SEQ ID NO 23, US 10,870,690 B2)

AAV-E5, recombinant AAV expressing human fibulin-3 variant with N-terminal FLAG-tag (SEQ ID 1, US 9,676,834 B2, Japan No. 6163565, China No. ZL201480010754.3, and European No. 2981335)